Knockdown of FLT4, Nup98, and Nup205 cellular genes as a suppressor for the viral activity of Influenza A/WSN/33 (H1N1) in A549 cell culture

Objectives. To evaluate the effect of cellular genes FLT4, Nup98, and Nup205 on the reproduction of the influenza A virus in A549 human lung cancer cell line.

Methods. The work was carried out using the equipment of the center for collective use of the I.I. Mechnikov Research Institute of Vaccines and Sera (Russia). The virus-containing fluid was collected within three days from the moment of transfection and infection and the intensity of viral reproduction was assessed by viral titration and hemagglutination reaction. The viral RNA concentration was determined by real-time reverse-transcription polymerase chain reaction (RT-PCR). To calculate statistically significant differences between groups, the nonparametric Mann–Whitney test was used.

Results. In cells treated with small interfering RNAs (siRNAs) targeted at FLT4, Nup98, and Nup205 genes, a significant decrease in their expression and indicators of viral reproduction (virus titer, hemagglutinating activity, viral RNA concentration) was observed at a multiplicity of infection (MOI) = 0.1. Additionally, it was found that a decrease in the expression of target genes using siRNA does not lead to a significant decrease in cell survival. The viral titer in cells treated with siRNA FLT4.2, Nup98.1, and Nup205 on the first day was lower by an average of 1.0 lg, and on the second and third days, by 2.2–2.3 lg, compared to cells treated with nonspecific siRNA. During real-time RT-PCR, a significant decrease in the concentration of viral RNA was observed with siRNA Nup98.1 (up to 190 times) and Nup205 (up to 30 times) on the first day, 26 and 29 times on the second day, and 6 and 30 times on the third day, respectively. For FLT4.2 siRNA, the number of viral RNA copies decreased by 23, 18, and 16 times on the first, second, and third days. Similar results were obtained when determining the hemagglutinating activity of the virus. The hemagglutinating activity on the third day most strongly decreased in cells treated with siRNA Nup205 and FLT4.2 (16 times). In cells treated with siRNA FLT4.1, Nup98.1, and Nup98.2, hemagglutinating activity decreased by 8 times.

Conclusions. In the present study, three cellular genes (FLT4, Nup98, and Nup205) were identified—the decrease in the expression of which effectively suppresses viral reproduction— and the original siRNA sequences were obtained. The results obtained are important for creating therapeutic and prophylactic medication, whose action is based on the RNA interference mechanism.

1. . Hussain M., Galvin H.D., Haw T.Y., Nutsford A.N., Husain M. Drug resistance in influenza A virus: the epidemiology and management. Infect. Drug Resist. 2017 Apr 20;10:121–134. https://doi.org/10.2147/IDR.S105473

2. Peasah S.K., Azziz-Baumgartner E., Breese J, Meltzer M.I., Widdowson MA. Influenza cost and cost-effectiveness studies globally – a review. Vaccine. 2013;31(46):5339–5348. https://doi.org/10.1016/j.vaccine.2013.09.013

3. Rezkalla S.H., Kloner R.A. Influenza-related viral myocarditis. WMJ. 2010;109(4):209–213. PMID: 20945722. URL: https://wmjonline.org/wp-content/uploads/2010/109/4/209.pdf

4. Nguyen J.L., Yang W., Ito K., Matte T.D., Shaman J., Kinney P.L. Seasonal Influenza Infections and Cardiovascular Disease Mortality. JAMA Cardiol. 2016;1(3):274–281. PMID: 27438105; PMCID: PMC5158013 https://doi.org/10.1001/jamacardio.2016.0433

5. Ekstrand J.J. Neurologic complications of influenza. Semin. Pediatr. Neurol. 2012;19(3):96–100. https://doi.org/10.1016/j.spen.2012.02.004

6. Edet A., Ku K., Guzman I., Dargham H.A. Acute Influenza Encephalitis/Encephalopathy Associated with Influenza A in an Incompetent Adult. Case Rep. Crit. Care. 2020;2020:6616805. https://doi.org/10.1155/2020/6616805

7. Err H., Wiwanitkit V. Emerging H6N1 influenza infection: renal problem to be studied. Ren. Fail. 2014;36(4):662. https://doi.org/10.3109/0886022X.2014.883934

8. Leneva I.А., Egorov A.Yu., Falynskova I.N., Маkhmudоvа N.R., Kartashova N.P., Glubokova E.A., Vartanova N.O., Poddubikov A.V. Induction of secondary bacterial pneumonia in mice infected with pandemic and laboratory strains of the H1N1 influenza virus. Zhurnal mikrobiologii, epidemiologii i immunobiologii = Journal of Microbiology, Epidemiology and Immunobiology. 2019;(1):68–74 (in Russ.). https://doi.org/10.36233/03729311-2019-1-68-74

9. Metersky M.L., Masterton R.G., Lode H., File T.M. Jr., Babinchak T. Epidemiology, microbiology, and treatment considerations for bacterial pneumonia complicating influenza. Int. J. Infect. Dis. 2012;16(5):e321–31. https://doi.org/10.1016/j.ijid.2012.01.003

10. Vanderbeke L., Spriet I., Breynaert C., Rijnders B.J.A., Verweij P.E., Wauters J. Invasive pulmonary aspergillosis complicating severe influenza: epidemiology, diagnosis and treatment. Curr. Opin. Infect. Dis. 2018;31(6):471–480. https://doi.org/10.1097/QCO.0000000000000504

11. Van der Vries E., Schutten M., Fraaij P., Boucher C., Osterhaus A. Influenza virus resistance to antiviral therapy. Adv. Pharmacol. 2013;67:217–246. https://doi.org/10.1016/B978-0-12-405880-4.00006-8

12. Han J., Perez J., Schafer A., Cheng H., Peet N., Rong L., Manicassamy B. Influenza Virus: Small Molecule Therapeutics and Mechanisms of Antiviral Resistance. Curr. Med. Chem. 2018;25(38):5115–5127. https://doi.org/10.2174/0929867324666170920165926

13. Looi Q.H., Foo J.B., Lim M.T., Le C.F., Show P.L. How far have we reached in development of effective influenza vaccine? Int. Rev. Immunol. 2018;37(5):266–276. https://doi.org/10.1080/08830185.2018.1500570

14. Pleguezuelos O., James E., Fernandez A., Lopes V., Rosas L.A., Cervantes-Medina A., Cleath J., Edwards K., Neitzey D., Gu W., Hunsberger S., Taubenberger J.K., Stoloff G., Memoli M.J. Efficacy of FLU-v, a broad-spectrum influenza vaccine, in a randomized phase IIb human influenza challenge study. NPJ Vaccines. 2020;5(1):22. https://doi.org/10.1038/s41541-020-0174-9

15. Wang F., Chen G., Zhao Y. Biomimetic nanoparticles as universal influenza vaccine. Smart Mater. Med. 2020;1:21–23. https://doi.org/10.1016/j.smaim.2020.03.001

16. Smith M. Vaccine safety: medical contraindications, myths, and risk communication. Pediatr. Rev. 2015;36(6):227–238.

17. Wang J., Wu Y., Ma C., Fiorin G., Wang J., Pinto L.H., et al. Structure and inhibition of the drug-resistant S31N mutant of the M2 ion channel of influenza A virus. Proc. Natl. Acad. Sci. USA. 2013;110(4):1315–1320. https://doi.org/10.1073/pnas.1216526110

18. Leneva I.A., Russell R.J., Boriskin Y.S., Hay A.J. Characteristics of arbidol-resistant mutants of influenza virus: Implications for the mechanism of anti-influenza action of arbidol. Antiviral Res. 2009;81(2):132–140. https://doi.org/10.1016/j.antiviral.2008.10.009

19. Hurt A.C., Ernest J., Deng Y.M., Iannello P., Besselaar T.G., Birch C., et al. Emergence and spread of oseltamivirresistant influenza A (H1N1) viruses in Oceania, Southeast Asia and South Asia. Antiviral Res. 2009;83(1):90–93. https://doi.org/10.1016/j.antiviral.2009.03.003

20. Hurt A.C. The epidemiology and spread of drug resistant human influenza viruses. Curr. Opin. Virol. 2014;8:22–29. https://doi.org/10.1016/j.coviro.2014.04.009

21. Lampejo T. Influenza and antiviral resistance: an overview. Eur. J. Clin. Microbiol. Infect. Dis. 2020;39(7):1201–1208. https://doi.org/10.1007/s10096-020-03840-9

22. Fire A.Z. Gene silencing by double-stranded RNA. Cell Death Differ. 2007;14(12):1998–2012. https://doi.org/10.1038/sj.cdd.4402253

23. Fire A., Xu S.Q., Montgomery M.K., Kostas S.A., Driver S.E., Mell C.C. Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans. Nature. 1998;391(6669): 806–811. https://doi.org/10.1038/35888

24. Faizuloev E.B., Nikonova A.A., Zverev V.V. Prospects for the development of antiviral drugs based on small interfering RNAs. Voprosy virusologii = Problems of Virology. 2013;(S1):155–169 (in Russ.). URL: https://cyberleninka.ru/article/n/perspektivy-sozdaniya-protivovirusnyh-preparatov-na-osnove-malyh-interferiruyuschih-rnk

25. McManus M.T., Sharp P.A. Gene silencing in mammals by small interfering RNAs. Nat. Rev. Genet. 2002;3(10):737–747. https://doi.org/10.1038/nrg908

26. Estrin M.A., Hussein I.T.M., Puryear W.B., Kuan A.C., Artim S.C., Runstadler J.A. Host-directed combinatorial RNAi improves inhibition of diverse strains of influenza A virus in human respiratory epithelial cells. PLoS One. 2018;13(5):e0197246. https://doi.org/10.1371/journal.pone.0197246

27. Janssen H.L., Reesink H.W., Lawitz E.J., Zeuzem S., Rodriguez-Torres M., Patel K., van der Meer A.J., Patick A.K., Chen A., Zhou Y., Persson R., King B.D., Kauppinen S., Levin A.A., Hodges M.R. Treatment of HCV infection by targeting microRNA. N. Engl. J. Med. 2013;368(18):1685–1394. https://doi.org/10.1056/nejmoa1209026

28. Qureshi A., Tantray V.G., Kirmani A.R., Ahangar A.G. A review on current status of antiviral siRNA. Rev. Med. Virol. 2018;28(4):e1976. https://doi.org/10.1002/rmv.1976

29. Hoy S.M. Patisiran: First Global Approval. Drugs. 2018;78(15):1625–1631. https://doi.org/10.1007/s40265-0180983-6

30. Lesch M., Luckner M., Meyer M., Weege F., Gravenstein I., Raftery M., Sieben C., Martin-Sancho L., ImaiMatsushima A., Welke R.W., Frise R., Barclay W., Schönrich G., Herrmann A., Meyer T.F, Karlas A. RNAi-based small molecule repositioning reveals clinically approved ureabased kinase inhibitors as broadly active antivirals. PLoS Pathog. 2019;15(3):e1007601. https://doi.org/10.1371/journal.ppat.1007601

31. Karlas A., Machuy N., Shin Y., Pleissner K.P., Artarini A., Heuer D., et al. Genome-wide RNAi screen identifies human host factors crucial for influenza virus replication. Nature. 2010;463(7282):818–822. https://doi.org/10.1038/nature08760

32. Arenas-Hernandez M., Vega-Sanchez R. Housekeeping gene expression stability in reproductive tissues after mitogen stimulation. BMC Res. Notes. 2013;6:285. https://doi.org/10.1186/1756-0500-6-285

33. Lee H.K., Loh T.P., Lee C.K., Tang J.W., Chiu L., Koay E.S. A universal influenza A and B duplex real-time RTPCR assay. J. Med. Virol. 2012;84(10):1646–1651. https://doi.org/10.1002/jmv.23375

34. Ramakrishnan M.A. Determination of 50% endpoint titer using a simple formula. World J. Virol. 2016;5(2):85–86. https://doi.org/10.5501/wjv.v5.i2.85

35. Eierhoff T., Hrincius E.R., Rescher U., Ludwig S., Ehrhardt C. The Epidermal Growth Factor Receptor (EGFR) promotes uptake of influenza А viruses (IAV) into host cells. PLoS Pathog. 2010;6(9):e1001099. https://doi.org/10.1371/journal.ppat.1001099

36. Shaw M.L., Stertz S. Role of Host Genes in Influenza Virus Replication. In: Tripp R., Tompkins S. (Eds.). Roles of Host Gene and Non-coding RNA Expression in Virus Infection. Current Topics in Microbiology and Immunology. 2017;419:151–189. https://doi.org/10.1007/82_2017_30

37. Watanabe T., Watanabe S., Kawaoka Y. Cellular networks involved in the influenza virus life cycle. Cell Host & Microbe. 2010;7(6):427–439. https://doi.org/10.1016/j.chom.2010.05.008

38. Hussain M., Galvin H.D., Haw T.Y., Nutsford A.N., Husain M. Drug resistance in influenza A virus: the epidemiology and management. Infect. Drug Resist. 2017;10:121–134. https://doi.org/10.2147/IDR.S105473

39. Sanjuán R., Domingo-Calap P. Mechanisms of viral mutation. Cell. Mol. Life Sci. 2016;73(23):4433–4448. https://doi.org/10.1007/s00018-016-2299-6

40. Presloid J.B., Novella I.S. RNA viruses and RNAi: quasispecies implications for viral escape. Viruses. 2015;7(6):3226–3240. https://doi.org/10.3390/v7062768

41. Das A.T., Brummelkamp T.R., Westerhout E.M., Vink M., Madiredjo M., Bernards R., et al. Human immunodeficiency virus type 1 escapes from RNA interferencemediated inhibition. J. Virol. 2004;78(5):2601–5. https://doi.org/10.1128/JVI.78.5.2601-2605.2004

42. Rupp J.C., Locatelli M., Grieser A., Ramos A., Campbell P.J., Yi H., et al. Host cell copper transporters CTR1 and ATP7A are important for Influenza A virus replication. Virol J. 2017;14(1):11. https://doi.org/10.1186/s12985-0160671-7

43. Wang R., Zhu Y., Zhao J., Ren C., Li P., Chen H., et al. Autophagy Promotes Replication of Influenza A Virus In Vitro. J. Virol. 2019;93(4):e01984–18. https://doi.org/10.1128/JVI.01984-18